JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ristocetin A, a glycopeptide related to vancomycin, is an antibiotic produced by the microorganism Nocardia lurida[1].
Ristocetin A is currently in clinical use to treat bacterial infections [1]. Ristocetin A is an antibiotic which can be used to treat staphylococcal infections. The side effects of ristocetin A include thrombocytopenia and platelet agglutination. Ristocetin A has been used in two assays: the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. These two assays could be used to diagnosis the von Willebrand disease and other bleeding disorders [2, 3]. The structural features of Ristocetin A are similar to vancomycin.
References:[1] Pearson A J, Heo J N. Approaches to the fully functionalized DEF ring system of ristocetin A via highly selective ruthenium-promoted SNAr reaction[J]. Organic letters, 2000, 2(19): 2987-2990.Hawks G H. Antibiotic therapy of staphylococcal infections[J]. Canadian Medical Association journal, 1965, 93(16): 848.[3] Castaman, G. ,Hillarp, A. and Goodeve, A. Laboratory aspects of von Willebrand disease: Test repertoire and options for activity assays and genetic analysis. Haemophilia 20(suppl 4), 65-70 (2014).